Related Experiment Video
Updated: Sep 17, 2025
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.4K
Mucin-1: a promising pan-cancer therapeutic target
Udhayvir Singh Grewal1, Razelle Kurzrock2
1Division of Hematology, Oncology, Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. udhayvir-grewal@uiowa.edu.
NPJ Precision Oncology
|July 3, 2025
Summary
Mucin1 (MUC1) protein is overexpressed in many cancers, driving tumor growth and spread. Novel MUC1-targeting therapies, including vaccines and antibodies, show promise in clinical studies for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Mucin1 (MUC1) is a transmembrane protein with aberrant expression and glycosylation in various solid and hematological malignancies.
- MUC1 overexpression is linked to cancer progression, promoting tumor cell migration, invasion, and accelerated growth through multiple signaling pathways.
- Tumor markers CA 27.29/CA 15-3, derived from MUC1, are utilized in monitoring breast cancer patients.
Purpose of the Study:
- To review the molecular mechanisms by which MUC1 contributes to cancer development and progression.
- To summarize the current landscape of MUC1-targeting therapeutic agents in clinical development.
- To provide an overview of novel strategies for MUC1-based cancer therapy.
Main Methods:
- Literature review of MUC1's role in cancer.
- Analysis of data from clinical studies on MUC1-targeting agents.
- Synthesis of information on molecular mechanisms and therapeutic pipelines.
Main Results:
- Abnormal MUC1 expression and glycosylation are key drivers of cancer cell aggressiveness.
- A diverse range of MUC1-targeted therapies are under investigation, including vaccines, cellular therapies, radiopharmaceuticals, monoclonal antibodies, and antibody-drug conjugates.
- These novel agents are progressing through various stages of clinical trials.
Conclusions:
- MUC1 is a significant molecular target in oncology due to its role in cancer progression.
- Emerging MUC1-targeting therapies represent a promising avenue for improving cancer treatment outcomes.
- Further research and clinical evaluation are crucial for the successful development of MUC1-based cancer therapeutics.
Related Concept Videos
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:38Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
599
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
599